The majority of solid tumors such as breast cancer [42], small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) overexpress VEGF-A, making it the dominant target for anti-angiogenic drugs [43,44]. This evidence concerns the gene VEGFA and small cell lung carcinoma.